Loading
PI
PetIQ, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Herrman Robert Michael, was filed 07 Sept 2022.
PetIQ, Inc.: what insiders have been doing
PetIQ, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at PetIQ, Inc. has published a filing in the past twelve months. The most recent one dates from 28 October 2024.
Our records for PetIQ, Inc. go back to 2021, with 10 purchases and 9 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
103
Thresholds
n/a
Buy Volume
€2M
10 ops. · all time
Sell Volume
€5M
9 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$948.8M
Gross profitUS$217.6M23% margin
Net incomeUS$1.8M0.2% margin
Last declaration on 28 October 2024
Declarations103 total
14,822 sharesClass A Common StockSEC:0000950103-24-015416:0
88,808 sharesClass A Common StockSEC:0000950103-24-015418:0
13,363 sharesClass A Common StockSEC:0000950103-24-015415:0
3,497 sharesClass A Common StockSEC:0000950103-24-015423:0
10,481 sharesClass A Common StockSEC:0000950103-24-015425:0
14,822 sharesClass A Common StockSEC:0000950103-24-015419:0
114,027 sharesClass A Common StockSEC:0000950103-24-015417:0
8,269 sharesClass A Common StockSEC:0000950103-24-015414:0
9,800 sharesClass A Common StockSEC:0000950103-24-015428:0
6,077 sharesClass A Common StockSEC:0000950103-24-015427:0
12,807 sharesClass A Common StockSEC:0000950103-24-015412:0
18,547 sharesClass A Common StockSEC:0000950103-24-015421:0
9,675 shares0Class A Common StockSEC:0001415889-24-024174:0
5,000 sharesClass A Common StockSEC:0001415889-24-022558:0
6,077 sharesClass A Common StockSEC:0001415889-24-021698:0
7,449 sharesClass A Common StockSEC:0001415889-24-021053:0
50,000 sharesClass A Common StockSEC:0001415889-24-020783:0
7,449 sharesClass A Common StockSEC:0001415889-24-018158:0
6,077 sharesClass A Common StockSEC:0001415889-24-017930:0
6,077 sharesClass A Common StockSEC:0001415889-24-017942:0
6,077 sharesClass A Common StockSEC:0001415889-24-018002:0
6,077 sharesClass A Common StockSEC:0001415889-24-017938:0
6,077 sharesClass A Common StockSEC:0001415889-24-017971:0
6,077 sharesClass A Common StockSEC:0001415889-24-018007:0
12,117 shares@ US$22.19100.0% of flowClass A Common StockSEC:0001415889-24-017494:0
25 of 103 declarations
About PetIQ, Inc.
PetIQ, Inc. (ticker: PETQ) is a United States-based company that was listed on the NASDAQ market and operated at the intersection of animal health, consumer health products, and veterinary services. The company built its investment case around affordable access to pet care, and described itself in SEC filings as a leading pet medication, product, and wellness company. Its business model was organized into two reporting segments: Products and Services. The Products segment covered the manufacturing and distribution of pet medications and health-and-wellness products, while the Services segment provided veterinary wellness services and related product sales directly to consumers.
PetIQ’s product platform was designed for scale. In its recent SEC filings, the company stated that its Products business distributed through more than 60,000 points of distribution across major U.S. retail and e-commerce channels. The portfolio included value-branded proprietary products as well as third-party brands for dogs and cats, spanning prescription medications, OTC medications, and wellness products. On the manufacturing side, PetIQ highlighted facilities in Omaha, Nebraska, and Springville, Utah, which supported domestic production and supply-chain control.
Read moreShow less
The Services business gave the company a distinct omnichannel angle. PetIQ operated a national veterinarian service platform at over 2,600 community clinic locations and wellness centers hosted by retail partners across 39 states. Those locations offered diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks. In practice, this combination of products plus services allowed PetIQ to target recurring pet-owner spending and to differentiate itself from pure-play consumer health brands.
Historically, PetIQ expanded through a mix of organic growth and strategic acquisitions, including the integration of veterinary-service capabilities that strengthened its retail and clinic footprint. Its competitive position was based on convenience, affordability, and broad retail penetration in the U.S. pet-health market. The company competed with large animal-health groups, private-label and branded consumer pet-product suppliers, and specialized veterinary service providers.
Recent corporate developments were significant. In 2024, PetIQ reported improving profitability and then announced on August 7, 2024 that it had entered into a definitive agreement to be acquired by Bansk Group in an all-cash transaction valued at approximately $1.5 billion, or $31.00 per share. PetIQ later announced on October 25, 2024 that the acquisition had closed, and PETQ was delisted. For investors, that matters: the name now stands as a case study in scaled U.S. pet-health consolidation, rather than a continuing public-equity opportunity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
